214 related articles for article (PubMed ID: 11091112)
1. Quantitative assessment of tumor metabolism using FDG-PET imaging.
Weber WA; Schwaiger M; Avril N
Nucl Med Biol; 2000 Oct; 27(7):683-7. PubMed ID: 11091112
[TBL] [Abstract][Full Text] [Related]
2. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.
Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM
Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility of metabolic measurements in malignant tumors using FDG PET.
Weber WA; Ziegler SI; Thödtmann R; Hanauske AR; Schwaiger M
J Nucl Med; 1999 Nov; 40(11):1771-7. PubMed ID: 10565769
[TBL] [Abstract][Full Text] [Related]
4. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET.
Vriens D; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e725-31. PubMed ID: 22330998
[TBL] [Abstract][Full Text] [Related]
8. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
9. Breast imaging with fluorine-18-FDG PET: quantitative image analysis.
Avril N; Bense S; Ziegler SI; Dose J; Weber W; Laubenbacher C; Römer W; Jänicke F; Schwaiger M
J Nucl Med; 1997 Aug; 38(8):1186-91. PubMed ID: 9255146
[TBL] [Abstract][Full Text] [Related]
10. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
11. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
14. FDG uptake, tumour characteristics and response to therapy: a review.
Smith TA
Nucl Med Commun; 1998 Feb; 19(2):97-105. PubMed ID: 9548192
[TBL] [Abstract][Full Text] [Related]
15. Test-Retest Variability in Lesion SUV and Lesion SUR in
Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
[TBL] [Abstract][Full Text] [Related]
16. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
17. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
18. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
[TBL] [Abstract][Full Text] [Related]
19. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?
Zhuang HM; Cortés-Blanco A; Pourdehnad M; Adam LE; Yamamoto AJ; Martínez-Lázaro R; Lee JH; Loman JC; Rossman MD; Alavi A
Nucl Med Commun; 2001 Oct; 22(10):1123-8. PubMed ID: 11567186
[TBL] [Abstract][Full Text] [Related]
20. FDG imaging.
Coleman RE
Nucl Med Biol; 2000 Oct; 27(7):689-90. PubMed ID: 11091113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
